Gesellschaftsrecht / M&A

Kapitalmarkt

Steuern

Finanzierungen

Anlageprodukte

ADC Therapeutics

Homburger News

20250619_ADC Therapeutics

Homburger advised ADC Therapeutics SA on its USD 100 m Private Placement of Common Shares and Pre-Funded Warrants

On June 12, 2024, ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company headquartered in Switzerland, announced the private placement of 13.0 m common shares and pre-funded warrants to purchase 15.7 m common shares, raising aggregate gross proceeds of USD 100 m.
The Homburger team was led by Daniel Häusermann (Corporate / M&amp;A, Capital Markets) and included Bianca Nedwed and Estelle Piccard (both Corporate / M&amp;A, Capital Markets) as well as Stefan Oesterhelt and Philippe Weber (both Tax).

Finanzmarktrecht

BeOne Medicines_bw_640x140

Share-Image Teamplate Deals-and-Cases

Homburger advised BeOne Medicines Ltd. on its redomiciliation to Switzerland

On May 27, 2025, BeOne Medicines Ltd., a global oncology company, officially completed its redomiciliation from the Cayman Islands to Basel, Switzerland, following shareholder approval on April 28, 2025. The redomiciliation to Switzerland strengthens BeOne’s presence and deepens its roots in a global biopharmaceutical hub, further enabling its growth strategy of bringing innovative medicines to patients around the world.
BeOne Medicines Ltd.&#8217;s American Depositary Shares are listed on the Nasdaq Global Select Market, each representing 13 ordinary shares of BeOne Medicines Ltd., each having a par value of USD 0.0001 per share (the “Ordinary Shares”), the Ordinary Shares are listed on The Stock Exchange of Hong Kong Limited, and the Ordinary Shares traded in Renminbi are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
The Homburger team was led by David Oser (Corporate / M&amp;A, Capital Markets) and included Bianca Nedwed and Kaiyan Yeo (both Corporate / M&amp;A, Capital Markets), Stefan Bindschedler and Benjamin Leisinger (Banking and Finance) as well as Stefan Oesterhelt and Juliette Buob (both Tax).

Regulierung

Arbeitsrecht und Vergütung für Führungskräfte

Healthcare / Life Sciences

novo-nordisk_web_640x140

Homburger and Novo Nordisk_Novo Holdings_Catalent

On December 18, 2024, Novo Nordisk announced that it has successfully completed its USD 11 bn acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalization of Novo Holdings&#8250; acquisition of Catalent, Inc., a global contract development and manufacturing organization. The three acquired sites are specialized in the sterile filling of drugs and are located in Anagni (Italy), Brussels (Belgium) and Bloomington IN (USA).
Novo Nordisk is a leading global healthcare company headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, built upon its heritage in diabetes.
Catalent is a global contract development and manufacturing organization headquartered in Somerset, New Jersey. The company has over 50 global sites and employs more than 18,000 people.
A Homburger team comprising Andreas Müller, Anna Peter, Simone Schmid, Bianca Nedwed, Florian Bruggisser and Maria Braun (all Corporate / M&amp;A), Allegra Arnold, Meret Horisberger and Harun Cetin (all Regulatory), Jeremy Reichlin (Employment) as well as Reto Heuberger, Juliette Buob and Philipp Stiegeler (all Tax) advised Novo Nordisk on the transaction.

Bianca
Nedwed

Homburger advised ADC Therapeutics SA on its USD 100 m Private Placement of Common Shares and Pre-Funded Warrants

Homburger advised BeOne Medicines Ltd. on its redomiciliation to Switzerland

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Join the Team

Bianca Nedwed

Karriere

Sprachen

Zulassung

Teams

BiancaNedwed

Homburger advised ADC Therapeutics SA on its USD 100 m Private Placement of Common Shares and Pre-Funded Warrants

Homburger advised BeOne Medicines Ltd. on its redomiciliation to Switzerland

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Join the Team

Bianca Nedwed

Karriere

Sprachen

Zulassung

Teams

Bianca
Nedwed